補(bǔ)體成分5a(C5a)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法)
Multiplex Assay Kit for Complement Component 5a (C5a) ,etc. by FLIA (Flow Luminescence Immunoassay)
（注：?jiǎn)未位鞙y(cè)多因子不超過(guò)8個(gè)指標(biāo) ）
- 編號(hào)ULMA388Ra
- 物種Rattus norvegicus (Rat，大鼠) 相同的名稱(chēng)，不同的物種。
- 實(shí)驗(yàn)方法雙抗夾心
- 反應(yīng)時(shí)長(zhǎng)3.5h
- 檢測(cè)范圍0.1-100ng/mL
- 靈敏度最小可檢測(cè)劑量小于等于0.033 ng/mL.
- 樣本類(lèi)型Serum, plasma and other biological fluids
- 下載 英文說(shuō)明書(shū) 中文說(shuō)明書(shū)
- 規(guī)格 8指標(biāo)數(shù) 7指標(biāo)數(shù) 6指標(biāo)數(shù) 5指標(biāo)數(shù) 4指標(biāo)數(shù) 3指標(biāo)數(shù) 2指標(biāo)數(shù)1指標(biāo)數(shù)
- 價(jià)格 ¥ 1281 ¥ 1330 ¥ 1404 ¥ 1502 ¥ 1601 ¥ 1749 ¥ 1970 ¥ 2463 添加到價(jià)格計(jì)算器 計(jì)算器
- 欲了解實(shí)際交易價(jià)格和更多情況，請(qǐng)與當(dāng)?shù)亟?jīng)銷(xiāo)商聯(lián)系!
-
產(chǎn)品包裝(模擬)
-
產(chǎn)品包裝(模擬)
-
通過(guò)ISO 9001、ISO 13485質(zhì)量體系認(rèn)證
特異性
本試劑盒用于檢測(cè)補(bǔ)體成分5a(C5a)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法)，經(jīng)檢測(cè)與其它相似物質(zhì)無(wú)明顯交叉反應(yīng)。
由于受到技術(shù)及樣本來(lái)源的限制，不可能完成對(duì)所有相關(guān)或相似物質(zhì)交叉反應(yīng)檢測(cè)，因此本試劑盒有可能與未經(jīng)檢測(cè)的其它物質(zhì)有交叉反應(yīng)。
回收率
分別于定值血清及血漿樣本中加入一定量的補(bǔ)體成分5a(C5a)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法)（加標(biāo)樣品），重復(fù)測(cè)定并計(jì)算其均值，回收率為測(cè)定值與理論值的比率。
| 樣本 | 回收率范圍(%) | 平均回收率(%) |
| serum(n=5) | 97-104 | 101 |
| EDTA plasma(n=5) | 91-105 | 99 |
| heparin plasma(n=5) | 96-105 | 101 |
| sodium citrate plasma(n=5) | 88-101 | 97 |
精密度
精密度用樣品測(cè)定值的變異系數(shù)CV表示。CV(%) = SD/mean×100
批內(nèi)差：取同批次試劑盒對(duì)低、中、高值定值樣本進(jìn)行定量檢測(cè),每份樣本連續(xù)測(cè)定20 次，分別計(jì)算不同濃度樣本的平均值及SD值。
批間差：選取3個(gè)不同批次的試劑盒分別對(duì)低、中、高值定值樣本進(jìn)行定量測(cè)定，每個(gè)樣本使用同一試劑盒重復(fù)測(cè)定8次，分別計(jì)算不同濃度樣本的平均值及SD值。
批內(nèi)差： CV<10%
批間差： CV<12%
線(xiàn)性
在定值血清及血漿樣本內(nèi)加入適量的補(bǔ)體成分5a(C5a)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法)，并倍比稀釋成1:2，1:4，1:8，1:16的待測(cè)樣本，線(xiàn)性范圍即為稀釋后樣本中補(bǔ)體成分5a(C5a)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法)含量的測(cè)定值與理論值的比率。
| 樣本 | 1:2 | 1:4 | 1:8 | 1:16 |
| serum(n=5) | 78-104% | 92-105% | 85-99% | 83-91% |
| EDTA plasma(n=5) | 86-101% | 82-90% | 78-92% | 86-101% |
| heparin plasma(n=5) | 87-101% | 94-101% | 90-99% | 78-89% |
| sodium citrate plasma(n=5) | 97-105% | 80-90% | 86-96% | 98-105% |
穩(wěn)定性
經(jīng)測(cè)定，試劑盒在有效期內(nèi)按推薦溫度保存，其活性降低率小于5%。
為減小外部因素對(duì)試劑盒破壞前后檢測(cè)值的影響，實(shí)驗(yàn)室的環(huán)境條件需盡量保持一致，尤其是實(shí)驗(yàn)室內(nèi)溫度、濕度及溫育條件。其次由同一實(shí)驗(yàn)員來(lái)進(jìn)行操作可減少人為誤差。
實(shí)驗(yàn)流程
1. 實(shí)驗(yàn)前標(biāo)準(zhǔn)品、試劑及樣本準(zhǔn)備；
2. 加樣（標(biāo)準(zhǔn)品、樣本、磁珠）標(biāo)準(zhǔn)品或樣本100μL及磁珠10μL，
37°C酶標(biāo)板振蕩器孵育90分鐘；
3. 磁吸甩干，加檢測(cè)溶液A100μL，37°C酶標(biāo)板振蕩器孵育60分鐘；
4. 磁吸洗板3次；
5. 加檢測(cè)溶液B100μL，37°C振動(dòng)孵育30分鐘；
6. 磁吸洗板3次；
7. 加鞘液100μL，旋渦震蕩2分鐘后讀數(shù)。
實(shí)驗(yàn)原理
將補(bǔ)體成分5a(C5a)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法)抗體包被于磁珠，制成固相載體，向微孔中分別加入標(biāo)準(zhǔn)品或標(biāo)本以及磁珠，其中的補(bǔ)體成分5a(C5a)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法)與連接于固相載體上的抗體結(jié)合，然后加入生物素化的補(bǔ)體成分5a(C5a)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法)抗體，將未結(jié)合的生物素化抗體洗凈后，加入PE標(biāo)記的親和素，再次徹底洗滌后即可上機(jī)讀數(shù)。MFI值和樣品中的補(bǔ)體成分5a(C5a)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法)呈正相關(guān)。
贈(zèng)品
增值服務(wù)
相關(guān)產(chǎn)品
| 編號(hào) | 適用物種：Rattus norvegicus (Rat，大鼠) | 應(yīng)用(僅供研究使用，不用于臨床診斷！) |
| UAPA388Ra61 | 補(bǔ)體成分5a(C5a)活性蛋白 | Cell?culture;?Activity?Assays. |
| UEPA388Ra61 | 補(bǔ)體成分5a(C5a)真核蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| URPA388Ra01 | 補(bǔ)體成分5a(C5a)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| URPA388Ra02 | 補(bǔ)體成分5a(C5a)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| UPAA388Ra01 | 補(bǔ)體成分5a(C5a)多克隆抗體 | WB; IHC |
| UPAA388Ra02 | 補(bǔ)體成分5a(C5a)多克隆抗體 | IHC |
| UPAA388Ra06 | 補(bǔ)體成分5a(C5a)多克隆抗體 | WB |
| ULAA388Ra81 | 補(bǔ)體成分5a(C5a)多克隆抗體(異硫氰酸熒光素標(biāo)記) | WB; IHC; ICC; IF. |
| ULAA388Ra71 | 補(bǔ)體成分5a(C5a)多克隆抗體(生物素標(biāo)記) | WB; IHC; ICC. |
| UMAA388Ra22 | 補(bǔ)體成分5a(C5a)單克隆抗體 | WB |
| UMAA388Ra23 | 補(bǔ)體成分5a(C5a)單克隆抗體 | WB |
| UMAA388Ra24 | 補(bǔ)體成分5a(C5a)單克隆抗體 | WB; IHC |
| UMAA388Ra25 | 補(bǔ)體成分5a(C5a)單克隆抗體 | WB; IHC |
| UMAA388Ra21 | 補(bǔ)體成分5a(C5a)單克隆抗體 | WB; IHC |
| USEA388Ra | 補(bǔ)體成分5a(C5a)檢測(cè)試劑盒(酶聯(lián)免疫吸附試驗(yàn)法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
| USCA388Ra | 補(bǔ)體成分5a(C5a)檢測(cè)試劑盒(化學(xué)發(fā)光免疫分析法) | Chemiluminescent immunoassay for Antigen Detection. |
| ULMA388Ra | 補(bǔ)體成分5a(C5a)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法) | FLIA Kit for Antigen Detection. |
參考文獻(xiàn)
| 雜志 | 參考文獻(xiàn) |
| Molecular Immunology | Cathepsin D is released after severe tissue trauma in vivo and is capable of generating C5a in vitro [ScienceDirect: S0161589011008297] |
| Journal of Reproductive Immunology | Elevated complement factor C5a in maternal and umbilical cord plasma in preeclampsia [PubMed: 23415845] |
| The Journal of Clinical Investigation | Complement component 5 contributes to poor disease outcome in humans and mice with pneumococcal meningitis [PubMed: PMC3195471] |
| Journal of Antimicrobial Chemotherapy | Efficacy of a synthetic antimicrobial peptidomimetic versus vancomycin in a Staphylococcus epidermidis device-related murine peritonitis model [Pubmed: 23645587] |
| Journal of Orthopaedic Research | Conversion from external fixator to intramedullary nail causes a second hit and impairs fracture healing in a severe trauma model [Pubmed: 23070742] |
| SpringerPlus | Therapeutic effects of sesame oil on monosodium urate crystal-induced acute inflammatory response in rats [Pubmed: 24353977] |
| American Journal fo Reproductive Immunology | Evaluation of the Markers of Inflammation in the Umbilical Cord Blood of Newborns of Mothers with Thrombophilia [Pubmed:25209155] |
| Gynecol Obstet Invest | Complement Split Products C3a/C5a and Receptors: Are They Regulated by Circulating Angiotensin II Type 1 Receptor Autoantibody in Severe Preeclampsia? [PubMed: 26485247] |
| Journal of Neuroimmunology | Acute and prolonged complement activation in the central nervous system during herpes simplex encephalitis [Pubmed:27235358] |
| International Immunopharmacology | Consistency and pathophysiological characterization of a rat polymicrobial sepsis model via the improved cecal ligation and puncture surgery [Pubmed:26802602] |
| Digital Repository | Dosagem de fra??es ativadas do sistema complemento em empiema induzido em ratos [10183] |
| Environmental Pollution | Cadmium-induced immune abnormality is a key pathogenic event in human and rat models of preeclampsia [pubmed:27511439] |
| Cancer Letters | Complement C5a/C5aR pathway potentiates the pathogenesis Q5 of gastric cancer by down-regulating p21 expression [pubmed:29031586] |
| Acta Paediatrica | Serum complement factor 5a levels are associated with nonalcoholic fatty liver disease in obese children [DOI:?10.1111/apa.14106] |
| Scientific Reports | Splenectomy modulates early immuno-inflammatory responses to trauma-hemorrhage and protects mice against secondary sepsis [Pubmed: 30291296] |
| Nutrients | The Beneficial Effects of Lactobacillus plantarum PS128 on High-Intensity, Exercise-Induced Oxidative Stress, Inflammation, and Performance in Triathletes [Pubmed: 30736479] |
| Journal of?NeuroVirology | Intrathecal complement activation by the classical pathway in tick-borne encephalitis [Pubmed: 30850976] |
| PLoS One | Sepsis causes right ventricular myocardial inflammation independent of pulmonary hypertension in a porcine sepsis model [Pubmed: 31247004] |
| Frontiers in Immunology | C5a/C5aR Pathway is Critical for the Pathogenesis of Psoriasis [Pubmed: 31447855] |
| Phytomedicine | Novel evidence that an alternative complement cascade pathway is involved in optimal mobilization of hematopoietic stem/progenitor cells in Nlrp3?… [] |
| Aging | C5aR deficiency attenuates the breast cancer development via the p38/p21 axis [Pubmed: 32669478] |
| STEM CELL REVIEWS AND REPORTS | A Novel Evidence That Mannan Binding Lectin (MBL) Pathway of Complement Cascade Activation is Involved in Homing and Engraftment of Hematopoietic Stem … [Pubmed: 32406006] |
| Modulation of C5a-C5aR interactions against murine mammary cancer cell line [] | |
| FASEB J | C‐reactive protein inhibits C3a/C3aR‐dependent podocyte autophagy in favor of diabetic kidney disease [Pubmed:35503088] |
